Year: 2026

Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) hastoday published its integrated Annual Report for 2025, including sustainabilityreporting and complete annual accounts with notes. The report is attached and available on the following website: https://arnarlax.is/investors/ For further information, please contact:CEO Bjørn HembreTel: +354 620 1936Email: bjorn@arnarlax.is Interim CFO Edvin AspliTel: +354 835 7800Email: edvinaspli@arnarlax.is Icelandic Salmon is dual-listed on the stock exchange market, both at the Euronext Growth in Oslo and NASDAQ First North in Reykjavík. The Group is the 100% owner of Arnarlax ehf, a farming company in Iceland with head office in Bíldudalur. The Group is fully integrated, from egg to fish delivered to customers in the market, with control over all parts of the value chain. See...

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offering, the “Equity Offering”). Zenas estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be...

SAINT-BRUNO-DE-MONTARVILLE, Québec, March 26, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) provided today an update regarding its sale and investment solicitation process (“SISP”) conducted under the supervision of the Superior Court of Québec (Commercial Division) (the “Court”) and Raymond Chabot Inc., as Court-appointed monitor of the Company (the “Monitor”) in connection with the restructuring proceedings (the “CCAA Proceedings”) of the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., instituted on January 8, 2026, under the Companies’ Creditors Arrangement Act (Canada). The Company continues to make progress with its SISP with the assistance of the Monitor, and has accepted four binding offers for the substantial...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026.Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences...

Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) — Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) today issues this statement regarding the ongoing investigation in Vietnam related to the ONUS Pro cryptocurrency platform (the “Platform”). The Company today learned of the indictments of Nhan (“Eric”) Vuong, Chairman of the Company’s Board of Directors, and Chien Tran, a member of the Company’s Board of Directors, through the official announcement by Vietnam’s Ministry of Public Security (the “MPS”) and Vietnamese news media, simultaneously with the general public. Prior to today, the Company had received no official communication from any authorities, law enforcement, or regulatory agencies in any jurisdiction regarding this matter. The Company...

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that the Company has granted, in the aggregate, 477,535 restricted share units (“RSUs”) and 32,738 deferred share units (“DSUs”) to directors and officers of the Company. The RSUs and DSUs granted to directors are scheduled to vest on a one-third per annum basis over a three-year period. The RSUs granted to officers are based on a combination of time and performance with 50% of the RSUs vesting 1/3 on the anniversary of the grant date over a period of three years and 50% of the RSUs vesting on the third anniversary of the grant date subject to achievement of certain key performance indicators as established by the Company’s Board of Directors. Each vested RSU entitles the holder to receive one share of the Company’s common stock...

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George...

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders Amsterdam, March 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced the resolutions to be submitted for adoption at the Annual General Meeting of Shareholders (AGM) which will be held in Amsterdam, the Netherlands, on May 27, 2026. The resolutions, proposed by the Supervisory Board, are:The adoption of the Company’s statutory annual accounts for the year ended December 31, 2025, prepared in accordance with International Financial Reporting Standards (IFRS). The 2025 statutory annual accounts1 were filed with the Netherlands Authority for the Financial Markets (AFM) on March 26, 2026 and are posted on the Company’s website...

SALT LAKE CITY, March 26, 2026 (GLOBE NEWSWIRE) — Datacentrex, Inc. (Nasdaq: DTCX) (“Datacentrex” or the “Company”), a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses, today announced the pricing of its confidentially marketed public offering (the “Offering”) of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, at a public offering price of $2.00 per share (inclusive of the pre-funded warrant exercise price). The Company expects to receive aggregate gross proceeds of $20.17 million from the Offering, before deducting placement agent fees and other related expenses. The Offering is expected to close on or about March 30,...